Lactobacillus strains and uses thereof

• US 7,846,711 B2
• Filed: 12/22/2006
• Issued: 12/07/2010
• Est. Priority Date: 12/22/2005
• Status: Active Grant

• Current Assignee: Novozymes A/S (Novozymes)
• Original Assignee: OrganoBalance GmbH
• Inventors: Veen, Markus, Lang, Christine, Budde, Eckhard, Boettner, Mewes, Ryser, Martin
• Primary Examiner(s): Afremova; Vera
• Application Number:
  US11/645,363
• Publication Number:
  US 20070148149A1
• Time in Patent Office: 1,446 Days
• Field of Search: None
• US Class Current: 435/252.9
• CPC Class Codes: A23C 9/1234 characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
• CPC Class Codes: A61K 2035/11 Medicinal preparations comprising living procariotic cells
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C12N 1/20 Bacteria; Culture media therefor
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12R 2001/225 Lactobacillus

Abstract

The invention concerns new isolated Lactobacillus cells, which are capable to aggregate Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.

Claims

1. Isolated Lactobacillus cells, which are capable of aggregating to Helicobacter pylori under culture conditions of the human digestive tract wherein the cells belong to one of the strains DSM 17646, DSM 17647, DSM 17648, DSM 17649, DSM 17650, DSM 17651, DSM 17652 or DSM 17653.

2. A pharmaceutical composition and/or dietetic composition comprising a physiologically effective dose of Lactobacillus cells according to claim 1 and a physiologically tolerated carrier.

3. The pharmaceutical composition of claim 2, wherein the composition contains 10² to 10¹⁵ Lactobacillus cells.

4. The pharmaceutical composition of claim 2, wherein the composition is prepared for oral administration.

5. The pharmaceutical composition of claim 2, wherein the Lactobacillus cells are lyophilized.

6. The pharmaceutical composition of claim 2, wherein the carrier is selected from the group consisting of maltodextrin, microcrystalline cellulose, starch, corn starch, levulose, lactose, dextrose, and mixtures of said carriers.

7. The pharmaceutical composition of claim 2, wherein the composition contains 0.1 to 95% by weight carrier and 5 to 99.9% by weight lyophilized Lactobacillus cells.

8. The dietetic composition of claim 2, wherein the composition contains 10² to 10¹⁵ Lactobacillus cells.

9. The dietetic composition of claim 2, wherein the physiologically tolerated carrier is a food material.

10. A method for producing a pharmaceutical and/or dietetic composition of claim 5, comprising mixing a physiologically effective quantity of the lyophilized Lactobacillus cells with the physiologically tolerated carrier and preparing the composition for oral administration.

11. A method for preventing and/or treating a person who suffers from a disease caused by a Helicobacter pylori infection or is suspected to fall ill with a disease caused by a Helicobacter pylori infection, comprising administering to the person a physiologically effective dose of a pharmaceutical and/or dietetic composition of claim 2 one to five times per day.

12. Isolated Lactobacillus cells of claim 1 which are capable of inhibiting the urease activity of Helicobacter pylori, wherein the pylori bacteria in the aggregates lose the ability to protect against the attack of stomach acid.

13. Isolated Lactobacillus cells according to claim 1, wherein the culture conditions are culture conditions of the stomach.

14. The pharmaceutical composition of claim 3, wherein the composition contains 10⁶ to 10¹² Lactobacillus cells.

15. The pharmaceutical composition of claim 3, wherein the composition contains 10⁸ to 10¹² Lactobacillus cells.

16. The pharmaceutical compositions of claim 3, wherein the composition contains 10⁸ to 10¹⁰ Lactobacillus cells.

17. The dietetic composition of claim 8, wherein the composition contains 10⁶ to 10⁹ Lactobacillus cells.

18. The dietetic composition of claim 8, wherein the composition contains 10⁷ to 10⁹ Lactobacillus cells.

19. The dietetic composition of claim 9, wherein the food material is selected from the group comprising milk products, fermented milk products, milk, yogurt, cheese, cereals, muesli bars, and children food preparations.

20. A method for producing a pharmaceutical and/or dietetic composition of claim 2, wherein a physiologically effective quantity of the Lactobacillus cells are mixed with the physiologically tolerated carrier and prepared for the oral administration.